Recently, selective estrogen receptor modulators have been developed for the management
of osteoporosis based on antiosteoclastic properties similar to that of estrogens but with a …

Context: Raloxifene is a promising breast cancer prevention agent in postmenopausal
women at increased risk for breast cancer. The effects of raloxifene in premenopausal …

Osteoporosis is a skeletal disorder characterized by compromised bone strength that
predisposes a person to increased fracture risk. Fractures are often associated with …

Selective estrogen-receptor modulators are molecules with specific estrogen-receptor
binding affinity. Each selective estrogen-receptor modulator induces a unique conformation …

In 1998, tamoxifen became the first drug to be FDA approved for use as a preventive agent
against cancer, when it was shown to reduce the incidence of breast cancer in women at …

Despite significant progress in breast cancer treatment, mammary tumours still represent the
second most frequent cause of cancer-related death in women in the US, with> 211,000 new …

The objective of this study was to evaluate the effects of raloxifene on normal breast tissue. A
randomized, double-blind study was carried out in 30 ovulatory, premenopausal women of …

Selective estrogen receptor modulators (SERMs) are a group of drugs with heterogeneous
structural chemical characteristics that are characterized as high-affinity ligands (in the …

Osteoporosis is a huge health care issue, especially with the aging of the" baby boom"
generation. Physician, as well as patient, awareness of bone health and preventing fragility …